Clinical effectiveness of magnesium orotate in patients with cardiac arrhythmias, arterial hypertension, and mitral valve prolapse

Abstract

Aim. To evaluate the effectiveness of magnesium orotate in the patients with cardiac arrhythmias, arterial hypertension (AH), and idiopathic mitral valve prolapse (MVP). Material and methods. The complex examination, dynamic follow-up, and placebo-controlled differentiated treatment were performed in 84 patients with idiopathic MVP. All participants underwent echocardiography, 24-hour blood pressure monitoring (BPM) and electrocardiography (ECG) monitoring, office BP measurement, spectral analysis of heart rate variability (HRV), and physical stress test. The main group (MG; n=43) received magnesium orotate (3000 mg/d) for 6 months; the comparison group (CG; n=41) received placebo. Results. According to the 24-hour ECG monitoring data, the treatment was associated with disappearance of high-grade arrhythmias and a 40% reduction in supraventricular (paroxysmal and non-paroxysmal) tachycardia incidence. The number of ventricular extrasystoles was reduced in 26%, and they disappeared in 54%. In 8%, polytopic ventricular extrasystoles were substituted by occasional monotopic extrasystoles. These changes were not observed in the CG patients. The percentage of Stage I AH patients decreased from 38% to 8% in the MG, and from 30% to 20% in the CG. Conclusion. In MVP patients, magnesium orotate treatment improved electro-physiological heart parameters, with reduced supraventricular and ventricular extrasystole incidence and improved circadian BP profile.

Keywords

• mitral valve prolapse
• cardiac arrhythmias
• arterial hypertension
• magnesium orotate